Thrombocytosis in solid tumors.

Trombocitosis en tumores sólidos.

Published 2020-02-01

Open | Download
PDF (Spanish) FLIP
Issue
Vol. 7 No. 1 (2020): Enero - Junio
Section
Original articles
How to Cite
Thrombocytosis in solid tumors.
Rev. colomb. hematol. oncol. [Internet]. 2020 Feb. 1 [cited 2024 Dec. 22];7(1):51-8. Disponible en: https://doi.org/10.51643/22562915.20
DOI

https://doi.org/10.51643/22562915.20
Dimensions
PlumX
license
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Jorge I. López
    Giovanny M. Caicedo
    Universidad Libre de Colombia
      Luis F. Cárdenas
      Universidad Libre de Colombia
        Juan M. Herrera
        Universidad Libre de Colombia
          Lisbeth P. Ramírez
          Universidad Libre de Colombia
            Show authors biography

            Jorge I. López

            Especialista en Medicina Interna y Geriatría. Especialista en Epidemiología

            Giovanny M. Caicedo,

            Grupo de Investigación en Hematooncología (GIHO). Especialización en Hematología y Oncología Clínica, Universidad Libre Seccional Cali (Cali, Colombia).

            Luis F. Cárdenas,

            Grupo de Investigación en Hematooncología (GIHO). Especialización en Hematología y Oncología Clínica, Universidad Libre Seccional Cali (Cali, Colombia).

            Juan M. Herrera,

            Grupo de Investigación en Hematooncología (GIHO). Especialización en Hematología y Oncología Clínica, Universidad Libre Seccional Cali (Cali, Colombia).

            Lisbeth P. Ramírez,

            Grupo de Investigación en Hematooncología (GIHO). Especialización en Hematología y Oncología Clínica, Universidad Libre Seccional Cali (Cali, Colombia).

            Eliana Ocampo Toro,

            Grupo de Investigación en Hematooncología (GIHO). Especialización en Hematología y Oncología Clínica, Universidad Libre Seccional Cali (Cali, Colombia).

            Margarita Velasco,

            Grupo de Investigación en Hematooncología (GIHO). Especialización en Hematología y Oncología Clínica, Universidad Libre Seccional Cali (Cali, Colombia).

            Álvaro J. Guerrero,

            Residente 2º año de Especialización en Hematología y Oncología Clínica. Universidad Libre (Cali, Colombia).

            Introduction: Platelets play a role in invasion and cancer. Thrombocytosis has been used as a paraneoplastic marker of inflammation and prognosis in solid tumors. Objective: To determine the relationship between thrombocytosis (>450 thousand cel/μl) with the clinical stage, metastasis and histopathology in patients with solid tumors. Methods: Analytical cross-sectional study, including 170 medical records, of patients not exposed to chemotherapy at diagnosis with solid tumors, describing clinical characteristics and the association of thrombocytosis with clinical stage, histological type, degree of differentiation, molecular profile and metastasis. The analyzes were performed with logistic regression, Stata version 12.0. Results: 76% female, median 63 years, median platelets of 249.000 cel/µl. breast cancer in 61.1%, prostate 12.3%, colon 15.8%, lung 5.88% and ovary 4.7%. Presence of metastasis in 37%, 23.5% with visceral metastasis, 13.5% with bone metastasis, and 4% of all patients with visceral and bone metastases. Thrombocytosis was associated with the presence of metastasis OR: 6.66 (CI: 1.29-34) p = 0.023; among the metastases, thrombocytosis was associated with visceral involvement OR: 6 (CI 1.36-26.3) p=0.018. There was no association of thrombocytosis with histological type, molecular profile in breast cancer, Gleason score in prostate cancer, or with bone metastases. Conclusions: The high value of platelets was associated in this study with the presence of visceral metastatic disease. It is necessary to expand the sample in order to confirm these results and perform studies that relate to therapeutic efficacy

            Article visits 3300 | PDF visits 2307

            1. Brewer DB, Schutze M, Bizzozero G. The discovery of the platelet, British Journal of Haematology. 2006;133:251-8.
            2. Izaguirre-Ávila R. El descubrimiento de las plaquetas. Historia de la Medicina Rev. Biomed.1997;8197-208.
            3. Burstein SA, Harker LA. Control of platelet production. Clin Haematol. 1983;12:3-22.
            4. Schafer A. Thombocytosis. N Engl J Med. 2004;350:1211-9.
            5. Álvarez JF, Bedoya-Trujillo N, Saldaña J. Enfoque clínico de la trombocitosis, una revisión de la literatura. Salutem Scientia Spiritus. 2018;4(1):41-48.
            6. Carrillo-Esper R, Garnica-Escamilla MA, Ramírez-Rosillo FJ, Trombocitosis. Rev Invest Med Sur Mex. 2013;20(4):254-6.
            7. Saavedra Ramírez G, Vásquez Duque GM, González Naranjo LA. Interleucina-6: ¿amiga o enemiga? bases para comprender su utilidad como objetivo terapéutico. Iatreia. 2011;24(2):157-66.
            8. Stone RL, Alpa MN, McNeish LA. Paraneoplastic thrombocytosis in ovarían cancer. N Engl J Med. 2012;366:610-8.
            9. Sarah ER, Obioha C. Clinical relevance of thrombocytosis in primary care. British Journal of General Practice. 2017;67(659):e405-13.
            10. Baileya SE, Ukoumunneb O, Sheparda E, Hamilton W. How useful is thrombocytosis in predicting an underlying cancer in primary care? A systematic review. Family Practice. 2017;34(1):4-105.
            11. Nash GF, Tornero LF, Scully MF, Kakkar A. Plaquetas y cáncer. Lancet Oncol. 2002;3:425-30.
            12. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in Globocan 2012. Int J Cancer. 2015;136(5):359-86.
            13. Siegel RL, Miller KD, Jemal A. Estadísticas de cáncer, 2018. CA Cancer J Clin. 2018;68:7.
            14. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. Globocan 2012, cancer incidence and mortality world wide. IARC Cancer Base. 2013;11:20.
            15. Gómez-Gómez B. Rodríguez-Weber FL, et al. Fisiología plaquetaria, agregometría. Med Int Méx. 2018;34(2):244-63.
            16. Miao-Zhen Qiu, Rui-Hua Xu, et al. Incidence of anemia, leukocytosis, and thrombocytosis in patients with solid tumors in China. Tumor biology. 2010;31(6):633-41.
            17. Tumor-platelet interaction in solid tumors. International Journal of Cancer. 2012;130(12):2747-60.
            18. Arrechea Irigoyen MA, et al. Molecular subtypes of breast cancer: prognostic implications and clinical and immunohistochemical characteristics. Anales Sis San Navarra. 2011;34(2).
            19. Blows FM, Driver KE, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010;7:e1000279.
            20. Huang W, Newman B, Millikan R. Risk of breast cancer according to the status of HER-2/neu oncogen amplification. Cancer Epidemiol Biomarkers Prev. 2000;9:65-71.
            21. Tsakountakis N, Sanidas E, Stathopoulos E. Correlation of breast cancer risk factors with HER2/NEU protein overexpression according to menopausal and estrogen receptor status. BMC Women Health. 2005;5:1-9.
            22. Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H. et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res. 2007;9:65.
            23. Wang YH, Deng SJ. Shao-jun Deng. The pretreatment thrombocytosis may predict prognosis of patients with colorectal cancer: a systematic review and meta-analysis. 2017;11(2).
            24. Fidler IJ. The patogénesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer. 2003;3(6):453-8.
            25. Anita R, Arpard S. Paraneoplastic thrombocytosis in breast cancer. Anticancer Research. 2013;33:4545-6.
            26. Benoy I, Salgado R, Colpaert C, Weytjens R, Vermeulen PB, Dirix LY. interleukin 6, plasma VEGF, serum VEGF, and platelet load in breast cancer patients. Clin Breast Cancer. 2002;2:311-5.
            27. Taucher S, Salat A, et. al. For the Austrian breast and colorectal cancer study: Impact of pretreatment thrombocytosis on survival in primary breast cancer. Thromb Haemost. 2003;89:1098-106.
            28. Kandemir EG, Mayadagli A, Karagoz B, Bilgi O, Turken O, Yaylaci M. Prognostic significance of thrombocytosis in node-negative colon cancer. J Int Med Res. 2005;33(2):228-35.
            29. Nyasavajjala SM, Runau F, Datta S, Annette H, Shaw AG, Lund JN. Is there a role for preoperative thrombocytosis in the treatment of colorectal cancer? Int J Surg. 2010;8:436-438.
            30. Ishizuka M, Nagata H, Takagi K, Iwasaki Y, Kubota K. Preoperative thrombocytosis is associated with survival after surgery for colorectal cancer. J Surg Oncol. 2012;106:887-91.
            31. Kandemir EG, Mayadagli A, Karagoz B, Bilgi O, Turken O, Yaylaci M. Significación pronóstica de la trombocitosis en el cáncer de colon con ganglios negativos. J Int Med Res. 2005;33:228-35.
            32. Qiu MZ, Yuan ZY, Luo HY, Ruan DY, Wang ZQ, Wang FH, Li YH, Xu RH. Impact of pretreatment hematologic profile on survival of colorectal cancer patients. Tumor Biol. 2010;31(4):255-60.
            33. Sasaki K, Kawai K, Tsuno NH, Sunami E, Kitayama J. Impact of preoperative thrombocytosis on the survival of patients with primary colorectal cancer. World J Surg. 2012;36:192-200.
            34. Maraz A, Furak J, Varga Z, Kahan Z, Tiszlavicz L, Hideghety K. La trombocitosis tiene un valor pronóstico negativo en el cáncer de pulmón. Anti Cáncer Res. 2013;33:1725-9.
            35. Crasta JA, Premlatha TS, Krishnan SM, Vallikad E, Rameshkumar K. Significance of preoperative thrombocytosis in epitelial ovarian cancer. Indian J Pathol Microbiol. 2010;53:546.
            36. Cohen JG, Tran AQ, Rimel BJ, Cass I, Walsh CS, Karlan BY, et al. Thrombocytosis at secondary cytoreduction for recurrent ovarian cancer predicts suboptimal resection and poor survival. Gynecol Oncol. 2014;132:5569.
            37. Gungor T, KanatPektas M, Sucak A, Mollamahmutoglu L. The role of thrombocytosis in prognostic evaluation of epitelial ovarian tumors. Arch Gynecol Obstet. 2009;279:536.
            38. Zeimet AG, Marth C, MüllerHolzner E, Daxenbichler G, Dapunt O. Significance of thrombocytosis in patients with epitelial ovarian cancer. Am J Obstet Gynecol. 1994;170:54954.
            39. Neal RD, Tharmanathan P, France B, et al. ¿El aumento del tiempo para el diagnóstico y tratamiento en el cáncer sintomático se asocia con resultados más pobres? Revisión sistemática. Br J Cancer. 2015;112(1):92-107.
            40. Kawano M, Mabuchi S, Matsumoto Y, Sasano T, Takahashi R, Kuroda H, et al. Prognostic significance of pretreatment thrombocytosis incervical cancer patients treated with definitive radiotherapy. Int J Gynecol Cancer 2015;25:165662.
            41. Humphrey PA. Cánceres de los órganos reproductores masculinos. En: informe sobre el cáncer en el mundo, Stewart BW, Wild CP, editors. Informe sobre el cáncer en el mundo. Lyon: Organización Mundial de la Salud; 2014.
            42. Gleason DF, Mellinger GT; Veterans Administration Cooperative Urological Research Group. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical Staging. J Urol. 2017;197(2S):S134-9.

            Information

            Directories and indexers
            Google Scholar profile

            QR code

            Keywords

            Most read in the last 30 days

            Current Issue

            Sistema OJS 3.4.0.7 - Metabiblioteca |